Equities

Xinjiang Bai Hua Cun Pharma Tech Co Ltd

600721:SHH

Xinjiang Bai Hua Cun Pharma Tech Co Ltd

Actions
TechnologyTechnology
  • Price (CNY)6.40
  • Today's Change-0.270 / -4.05%
  • Shares traded37.85m
  • 1 Year change+2.56%
  • Beta0.4313
Data delayed at least 15 minutes, as of Mar 13 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Xinjiang Bai Hua Cun Pharma Tech Co Ltd is a China-based company principally engaged in pharmaceutical services. The Company's main business is the research and development, registration and application of small molecule chemicals and the development of peptide drugs. The Company is engaged in the early discovery and screening of new drugs, drug clinical trials, biological sample analysis, medicine testing services, active pharmaceutical ingredient (API) and intermediate supply. The Company is also engaged in leasing and property services. The Company mainly conducts business within the domestic market.

  • Revenue in CNY (TTM)359.24m
  • Net income in CNY-28.06m
  • Incorporated1996
  • Employees731.00
  • Location
    Xinjiang Bai Hua Cun Pharma Tech Co LtdNo. 1 South Lane, Zhongshan RoadWULUMUQI 830002ChinaCHN
  • Phone+86 9 912356608
  • Fax+86 9 912356601
  • Websitehttp://www.xjbhc.net/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Jiangsu Cowin Biotech Co Ltd275.10m-21.54m2.03bn603.0049.441.19--7.390.36530.36533.5015.180.20061.872.29456,221.80-0.6891---0.7476--64.21---3.43--15.50--0.0193--54.11--26.55------
Hanshang Group Co Ltd1.39bn61.21m2.03bn2.11k32.961.21--1.460.20910.20914.715.710.38642.607.54--1.471.992.543.8859.0757.283.794.860.332.300.3308--0.18935.14-30.8325.6212.88--
Shanghai Shen Lian Biomedical Corp281.44m25.86m2.05bn365.0079.241.36--7.280.0630.0630.68543.660.17310.74740.9025771,056.401.546.851.657.5470.6479.218.9229.636.58--0.000830.78-8.321.70-44.56-9.14-2.08--
Jiangsu gdk Biotechnology Co Ltd33.39m-128.83m2.07bn451.00--1.54--62.10-1.04-1.040.268610.950.01930.41850.152974,034.57-7.453.30-8.734.8451.1475.56-385.8312.583.20--0.04832.60-57.74---270.88--54.07--
Xinjiang Bai Hua Cun Pharma Tech Co Ltd359.24m-28.06m2.10bn731.00--2.95--5.84-0.0746-0.07460.94951.860.34941.231.69491,437.10-2.73-15.65-3.73-20.4743.5526.36-7.80-67.381.42--0.0023--24.36-3.56-158.09---46.45--
Frontier Biotechnologies Inc114.25m-328.96m2.24bn395.00--1.67--19.64-0.8782-0.87820.3053.580.05021.472.30289,239.40-14.46-14.05-16.90-15.7826.222.35-287.93-450.082.75--0.2208--34.82126.637.79--28.13--
Data as of Mar 13 2024. Currency figures normalised to Xinjiang Bai Hua Cun Pharma Tech Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

0.13%Per cent of shares held by top holders
HolderShares% Held
Western Leadbank Fund Management Co., Ltdas of 30 Jun 2023469.70k0.13%
GF Fund Management Co., Ltd.as of 30 Jun 2023400.000.00%
Data from 30 Jun 2023 - 30 Jun 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.